CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体-抗体-抗体-生物在线
CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体

CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体

商家询价

产品名称: CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体

英文名称: Anti-CLN5 antibody

产品编号: HZ-11714R

产品价格: null

产品产地: 中国/美国

品牌商标: HZbscience

更新时间: 2023-08-17T10:24:20

使用范围: WB,ELISA,IHC-P,IHC-F,IF

上海沪震实业有限公司
  • 联系人 : 鲍丽雯
  • 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
  • 邮编 : 200612
  • 所在区域 : 上海
  • 电话 : 139****0749
  • 传真 : 021-60345367
  • 邮箱 : www.shzbio.net

CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体

产品编号HZ-11714R
英文名称CLN5
中文名称神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体
别 名Ceroid lipofuscinosis neuronal 5; Ceroid-lipofuscinosis neuronal protein 5; CLN5; CLN5_HUMAN; NCL; Protein CLN5.
说 明 书0.1ml 0.2ml
研究领域细胞生物 神经生物学
抗体来源Rabbit
克隆类型Polyclonal
交叉反应Human, Mouse, Rat, Pig, Cow, Horse, Rabbit, Sheep,
CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体产品应用WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量37kDa
细胞定位细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthetic peptide derived from human CLN5 (61-120aa)
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体PubMedPubMed
产品介绍background:
Neuronal ceroid-lipofuscinose (NCL), also designated Batten disease, comprises a group of recessively inherited, progressive neurodegenerative diseases found in children. NCL is characterized by atrophy of the brain and an accumulation of lysosome derived fluorescent bodies found in many cells, especially neurons. Symptoms of NCL include a failure of psychomotor development, seizures, impaired vision and premature death. The eight genes/proteins associated with NCL are designated CLN1-CLN8. Mutations in six of these genes results in a distinct type of NCL-disease; the six genes/proteins are CLN1 (encoding PPT1, a protein thiolesterase), CLN2 (encodeing the serine protease TPP1), CLN3, CLN5, CLN6 and CLN8. A single base duplication mutation in dog and cow CLN5 has been shown to cause NCL.

Subcellular Location:
Lysosome.

Tissue Specificity:
Ubiquitous.

Post-translational modifications:
Glycosylated.

CLN5,神经细胞蜡样质脂褐质沉积病蛋白CLN5抗体DISEASE:
Defects in CLN5 are the cause of neuronal ceroid lipofuscinosis type 5 (CLN5) [MIM:256731]; also known as Finnish variant late-infantile neuronal ceroid lipofuscinosis (vLINCL). A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 5 comprise mixed combinations of granular, curvilinear, and fingerprint profiles.

Similarity:
Belongs to the CLN5 family.

Database links:
UniProtKB/Swiss-Prot: O75503.2

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.